12:00 AM
Jun 03, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Halaven eribulin mesylate: Final Phase II data

Final data from 64 evaluable patients in a single-arm, open-label, U.S. Phase II trial showed that IV Halaven as an adjuvant to oral capecitabine met the primary endpoint of feasibility defined as >=80% of patients achieving an RDI of >=85% with a lower-bound 95% CI of >70%. Specifically, 81% of patients achieved an RDI of...

Read the full 253 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >